Cargando…

Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers

This phase I clinical trial (NCT01935843) is to evaluate the safety, feasibility, and activity of chimeric antigen receptor-engineered T cell (CART) immunotherapy targeting human epidermal growth factor receptor 2 (HER2) in patients with advanced biliary tract cancers (BTCs) and pancreatic cancers (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Kaichao, Liu, Yang, Guo, Yelei, Qiu, Jingdan, Wu, Zhiqiang, Dai, Hanren, Yang, Qingming, Wang, Yao, Han, Weidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Higher Education Press 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160389/ https://www.ncbi.nlm.nih.gov/pubmed/28710747 http://dx.doi.org/10.1007/s13238-017-0440-4

Ejemplares similares

Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment
por: Guo, Yelei, et al.
Publicado: (2017)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
por: Wei, Jianshu, et al.
Publicado: (2019)

Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
por: Wang, Zhenguang, et al.
Publicado: (2017)

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects
por: Guo, Yelei, et al.
Publicado: (2016)

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
por: Dai, Hanren, et al.
Publicado: (2015)

Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
por: Feng, Kaichao, et al.
Publicado: (2020)

The Role of HER2 Status in the Biliary Tract Cancers
por: Ayasun, Ruveyda, et al.
Publicado: (2023)

Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
por: Song, Yanjing, et al.
Publicado: (2017)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation
por: Jia, Hejin, et al.
Publicado: (2019)

Mutant B2M‐HLA‐E and B2M‐HLA‐G fusion proteins protects universal chimeric antigen receptor‐modified T cells from allogeneic NK cell‐mediated lysis
por: Guo, Yelei, et al.
Publicado: (2021)

Chimeric antigen receptor modified T-cells for cancer treatment
por: Han, Xiao, et al.
Publicado: (2018)

Bile is a reliable and valuable source to study cfDNA in biliary tract cancers
por: Li, Zhanghui, et al.
Publicado: (2022)

Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer
por: Kato, Shunsuke
Publicado: (2021)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2022)

HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer
por: Xu, Jie, et al.
Publicado: (2021)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
por: Dai, Hanren, et al.
Publicado: (2020)

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
por: Lamarca, Angela, et al.
Publicado: (2018)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
por: Harding, James J., et al.
Publicado: (2023)

MicroRNA Markers for the Diagnosis of Pancreatic and Biliary-Tract Cancers
por: Kojima, Motohiro, et al.
Publicado: (2015)

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
por: Gómez-España, Mª A., et al.
Publicado: (2021)

Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia
por: Cai, Bo, et al.
Publicado: (2016)

Correction: The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
Publicado: (2019)

The Role of Circular RNAs in Pancreatic Ductal Adenocarcinoma and Biliary-Tract Cancers
por: Limb, Christopher, et al.
Publicado: (2020)

Prevalence estimates of Helicobacter species infection in pancreatic and biliary tract cancers
por: Osaki, Takako, et al.
Publicado: (2022)

Clinical characteristics of pancreatic and biliary tract cancers associated with Lynch syndrome
por: Takamizawa, Shigemasa, et al.
Publicado: (2021)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
por: Pang, Yanyu, et al.
Publicado: (2018)

Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
por: Liu, Dongfang, et al.
Publicado: (2017)

Updates in Biliary Tract Cancers
por: Li, Daneng, et al.
Publicado: (2022)

Dysbiosis of the Fecal and Biliary Microbiota in Biliary Tract Cancer
por: Ito, Zensho, et al.
Publicado: (2022)

Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens
por: Aruga, Atsushi
Publicado: (2013)

Sociodemographic Trends in the Incidence of Pancreatic and Biliary Tract Cancer in UK Primary Care
por: Keane, Margaret G., et al.
Publicado: (2014)

Erratum to: Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
por: Liu, Dongfang, et al.
Publicado: (2017)

Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix
por: Zhang, Wenlong, et al.
Publicado: (2019)

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
por: Yan, Xin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g6g3k7p2dk0bp1qtse8na4ljq6